DailyStocks Stock Article Search

https://www.zacks.com/stock/news/2271790/anaptysbio-inc-anab-reports-q1-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2271790 May 09, 2024 - AnaptysBio (ANAB) delivered earnings and revenue surprises of -6.49% and 57.78%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock? 0

https://www.zacks.com/stock/news/2271052/cytek-biosciences-inc-ctkb-reports-q1-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2271052 May 08, 2024 - Cytek Biosciences (CTKB) delivered earnings and revenue surprises of 80% and 2.28%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock? 0

https://www.zacks.com/stock/news/2269884/guardant-gh-gears-up-for-q1-earnings-here-s-what-to-expect?cid=CS-ZC-FT-analyst_blog|earnings_preview-2269884 May 07, 2024 - Investors' focus will likely be on revenues generated by Guardant Health (GH) from its precision oncology testing business. 0

https://www.zacks.com/stock/news/2268852/iovance-iova-gears-up-for-q1-earnings-here-s-what-to-expect?cid=CS-ZC-FT-analyst_blog|earnings_preview-2268852 May 06, 2024 - Investors' focus will likely be on Iovance's (IOVA) progress with its ongoing commercial launch for a recently approved melanoma drug. An update is also expected on its early-stage pipeline. 0

https://www.zacks.com/stock/news/2240910/what-makes-anaptysbio-inc-anab-a-new-buy-stock?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2240910 Mar 14, 2024 - AnaptysBio, Inc. (ANAB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). 0

https://www.zacks.com/stock/news/2238869/anaptysbio-inc-anab-reports-q4-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2238869 Mar 11, 2024 - AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of 8.62% and 174.29%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock? 0

https://www.zacks.com/stock/news/2233958/analysts-estimate-lexicon-pharmaceuticals-lxrx-to-report-a-decline-in-earnings-what-to-look-out-for?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2233958 Feb 29, 2024 - Lexicon (LXRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. 0

https://www.zacks.com/stock/news/2233279/anaptysbio-inc-anab-expected-to-beat-earnings-estimates-should-you-buy?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2233279 Feb 28, 2024 - AnaptysBio, Inc. (ANAB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. 0

https://www.zacks.com/stock/news/2227661/strength-seen-in-anaptysbio-inc-anab-can-its-5-9-jump-turn-into-more-strength?cid=CS-ZC-FT-tale_of_the_tape|daily_price_change_5%-2227661 Feb 19, 2024 - AnaptysBio, Inc. (ANAB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. 0

https://www.zacks.com/stock/news/2207538/corcept-cort-stock-rises-on-upbeat-revenue-guidance-for-2024?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2207538 Jan 09, 2024 - Corcept (CORT) issues encouraging preliminary results for the fourth quarter and full-year 2023. Shares of the company rise on robust 2024 revenue guidance. 0